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ABSTRACT
Background: CTCs are a promising alternative for metastatic tissue biopsies for 
use in precision medicine approaches. We investigated to what extent the molecular 
characteristics of circulating tumor cells (CTCs) resemble the liver metastasis and/
or the primary tumor from patients with metastatic colorectal cancer (mCRC).
Results: The CTC profiles were concordant with the liver metastasis in 17/23 
patients (74%) and with the primary tumor in 13 patients (57%). The CTCs better 
resembled the liver metastasis in 13 patients (57%), and the primary tumor in five 
patients (22%). The strength of the correlations was not associated with clinical 
parameters. Nine genes (CDH1, CDH17, CDX1, CEACAM5, FABP1, FCGBP, IGFBP3, 
IGFBP4, and MAPT) displayed significant differential expressions, all of which were 
downregulated, in CTCs compared to the tissues in the 23 patients.
Patients and Methods: Patients were retrospectively selected from a prospective 
study. Using the CellSearch System, CTCs were enumerated and isolated just prior 
to liver metastasectomy. A panel of 25 CTC-specific genes was measured by RT-
qPCR in matching CTCs, primary tumors, and liver metastases. Spearman correlation 
coefficients were calculated and considered as continuous variables with r=1 
representing absolute concordance and r=-1 representing absolute discordance. A 
cut-off of r>0.1 was applied in order to consider profiles to be concordant.
Conclusions: In the majority of the patients, CTCs reflected the molecular 
characteristics of metastatic cells better than the primary tumors. Genes involved 
in cell adhesion and epithelial-to-mesenchymal transition were downregulated in 
the CTCs. Our results support the use of CTC characterization as a liquid biopsy for 
precision medicine.
INTRODUCTION
The treatment of metastatic colorectal cancer 
(mCRC) increasingly depends on the tumor’s molecular 
characteristics. For example, inhibition of the Epidermal 
Growth Factor Receptor (EGFR) by cetuximab or 
panitumumab was shown to be futile in the 30-60% of 
mCRC patients with KRAS or NRAS mutated tumors, 
and as such, these treatments are now indicated only for 
patients with wild-type tumors [1, 2]. Other tumor cell 
characteristics besides gene mutations may further affect 
patient outcome, as evidenced by a recent study showing 
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the ability of a gene expression profile to predict outcome 
to chemotherapy in mCRC patients [3]. One may argue 
that treatment decisions are best based on the composite 
picture of several molecular features, including DNA 
mutations and transcription levels.
Blood sampling for circulating tumor cells 
(CTCs) has widely been proposed as a “liquid biopsy” 
to guide treatment decisions. In addition to the CTC 
count, which is strongly prognostic for survival in 
patients with mCRC as determined by the CellSearch 
System (Janssen Diagnostics, Raritan, NJ) [4], CTCs 
are generally thought to provide a real-time picture of 
different tumor characteristics, including the extent of 
heterogeneity at specific moments [5]. However, solid 
proof that CTCs can indeed function as surrogates for 
metastatic tissue is currently lacking, since research on 
the biology and predictive value of CTCs is hampered by 
technical difficulties. The characterization of CTCs is very 
challenging due to the rarity of CTCs in the circulation 
and the large background of leukocytes in which they are 
left even after CellSearch enrichment [6-9]. In this study, 
we used our previously described approach to reliably 
measure the expression of tumor-associated genes in 
CellSearch-enriched CTCs to compare the molecular 
characteristics of CTCs with the primary tumor and a liver 
metastasis from patients with mCRC. We investigated 
whether the characteristics of CTCs taken at the time of 
metastatic disease were closer to the liver metastasis or 
the primary tumor and, in this respect, whether or not we 
can use CTCs as surrogates for metastatic tissue biopsies.
RESULTS
A total of 142 patients were included in the original 
prospective study investigating the prognostic value of 
the CTC count [10]. Archived formalin-fixed paraffin-
embedded (FFPE) primary tumor and liver metastasis 
tissues with ≥30% tumor cells on haematoxylin and eosin 
(HE) slides were available from 36 patients (Figure 1). 
Only patients with truly CTC-driven profiles from the 
CellSearch-enriched peripheral blood were selected for the 
comparison of the CTC profiles with the primary tumor 
and liver metastasis profiles. To this end, we calculated 
epithelial scores from the CTC samples as an indication 
for tumor cell input. Samples with an epithelial score 
above the established cut-off were selected (see methods 
section and Figure 2A-2D). The epithelial score was 
below the cut-off in 13 patients, leaving 23 patients with 
a reliable CTC-driven gene expression profile suitable for 
comparison with the primary tumor and liver metastasis 
(Figure 2D). The characteristics of these patients are 
shown in Table 1.
To compare the concordance of the three profiles per 
patient, heatmaps were constructed to show the relative 
height of the expression levels per gene in the different 
tumor compartments. Spearman correlation coefficients over 
the 25 ranks were calculated and considered as continuous 
variables with r=1 representing absolute concordance and 
r=-1 representing absolute discordance (Figure 3; Table 2). 
With a cut-off of r>0.1, the CTC profiles were concordant 
with the liver metastasis in 17 patients (74%) and with the 
primary tumor in 13 patients (57%). The primary tumor and 
metastasis profiles were concordant in 16 of the 23 patients 
(70%). Comparing the correlation coefficients from the 
correlation between the CTC versus primary tumor profiles 
and the CTC versus liver metastasis profiles with an error 
margin of ∆r>0.1, the CTCs more closely resembled the 
metastasis in 13 patients (57%) and the primary tumor in 
five patients (22%; Table 2). In the remaining five patients, 
the ∆r was ≤0.1 and/or both coefficients were ≤0.1. In 
patients 1 and 20, the CTCs neither resembled the primary 
tumor nor the liver metastasis. In patients 9, 14, and 17, 
both correlations seemed similar and the CTCs seemed to 
reflect both the characteristics from the primary tumor as 
well as the liver metastasis.
We next examined whether clinicopathological 
parameters were associated with the strength of the 
correlations. The primary tumor was still in situ at the 
time of liver surgery and CTC sampling in five patients 
(Table 2). Here, the CTCs could be theoretically derived 
from both the primary tumor and the metastases. In two 
patients, the CTCs seemed to share characteristics with 
both the primary tumor and the liver metastasis, as defined 
by a positive correlation of r>0.1 with both the primary 
tumor and the liver metastasis. In patients 10 and 19, the 
CTCs correlated with the liver metastasis only, whereas 
in patient 18, the CTC characteristics correlated with the 
primary tumor only. No associations of the correlations’ 
strength were observed regarding time or pattern of 
presentation with metastasis, the number of metastases, 
prior chemotherapy, or age (Table 3).
Lastly, we investigated the 25 individual genes for 
differences in expression levels between the three tumor 
compartments. For this, we calculated the difference 
between the ranks of two samples (∆rank) per gene per 
patient and the mean of the ∆ranks over the 23 patients. 
This resulted in three mean ∆ranks per gene (CTC-primary 
tumor, CTC-metastasis, metastasis-primary tumor; Table 4). 
In an instance where a gene was not differentially expressed 
between two tumor compartments, the mean ∆rank would 
be close to and not statistically significantly different from 
zero. A one-sample t test against 0 was applied to determine 
whether genes were significantly over- or under-expressed 
(Table 4). The expression levels between the primary tumor 
and the liver metastases were overall similar; only FCGBP 
was downregulated in the liver metastases. In the CTCs, 
however, a larger number of genes was downregulated. In 
comparison to the primary tumor, the expression of CDH1, 
CDH17, CDX1, CEACAM5, FABP1, FCGBP, IGFBP3, 
IGFBP4, and MAPT were downregulated. Compared to the 
liver metastases, downregulations of the same genes were 
observed, with the exceptions of FCGBP and IGFBP4.
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DISCUSSION
In this study, we observed that the molecular 
characteristics of CTCs obtained just prior to liver 
metastasectomy well reflected the characteristics of (one 
of) the liver metastasis and were generally closer to the 
metastasis than the primary tumor in patients with mCRC. 
Based on the expression of 25 CTC-specific and tumor-
associated genes, we found the CTC profiles to correlate 
with the liver metastasis in 74% of the patients and with 
the primary tumor in 57% of the patients. No associations 
were observed between the strength of the correlations and 
clinicopathological characteristics.
To gain insight into the molecular changes 
occurring during tumor progression, we investigated the 
differences in the expression levels of the 25 individual 
genes between the three tumor compartments. Nine genes 
were downregulated in the CTCs, three of which (CDH1, 
CDH17, CEACAM5) are involved in cell adhesion. 
Downregulation of CDH1, encoding E-Cadherin, is a 
well-recognized event in the progression of epithelial 
cancers and the induction of epithelial-to-mesenchymal 
transition (EMT) [11, 12]. The loss of epithelial markers, 
including E-cadherin, together with an overexpression of 
mesenchymal markers has been consistently observed in 
CTCs and is thought to reflect EMT as a means for CTCs 
to survive in the circulation [13-16]. Downregulation 
of insulin growth factor binding proteins 3 (IGFBP3) 
and 4 (IGFBP4), both proliferation-inhibiting and 
apoptosis-inducing factors, may help CTCs to survive 
[17]. Additionally, IGFBP3/4 may play a role in EMT 
through interactions with the EMT-inducer transforming 
growth factor β (TGF-β) [17, 18]. The significance 
of the downregulation of CDX1, FABP1, and MAPT 
in CTCs is unknown, although associations between 
the losses of these genes and the development and 
progression of colon cancer have been described [19-26]. 
Altogether, most of the downregulated genes in the 
CTCs seem to act as tumor suppressors, cell adhesion 
molecules, or have an involvement in EMT, a process 
that has well-acknowledged relevance for the survival 
and dissemination of CTCs [14, 15]. The observed 
downregulations thus seem to have a functional role in 
CTC biology.
Figure 1: Study flowchart and the selection of patients for the analyses. The selection of patients with a gene expression profile 
from the CTCs, the primary tumor, and the liver metastasis was further based on the presence of sufficient epithelial signals in the CTC 
samples, as a measure for the presence of CTCs amongst the leukocytes (also see Figure 2). Of the 36 patients, 23 were designated as having 
an “HBD”-unlike and reliably CTC-driven profile. These patients were included in the analyses to compare the gene expression profiles of 
the CTCs to the primary tumors and the liver metastases.
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Figure 2: The selection of patients with CTC-driven profiles from the blood samples of the total 36 selected patients. 
Only patients with sufficient epithelial input were included in the analyses to compare gene expression profiles with CTCs, the primary 
tumor, and a liver metastasis. A. An epithelial score was calculated by adding the expression levels of the 34 CTC-specific genes multiplied 
by the z-value from the comparison between 23 patients with ≥3 CTCs and using the 30 HBDs from the prior study [8] as a weighing 
factor. The epithelial scores from the 23 patients with ≥3 CTCs and the 30 HBDs strongly correlated with the CTC count from the blood 
tube taken in parallel with the tubes for the characterization of CTCs (r=0.76, P<0.001). B. A Receiver Operating Characteristics (ROC) 
curve was constructed from the epithelial scores of the 23 patients with ≥3 CTCs and the 30 HBDs. The optimal cut-off value resulted in 
a sensitivity of 91% and a specificity of 93% to discriminate patients from HBDs. C. Line graph showing the epithelial scores of the 23 
patients with ≥3 CTCs and the 30 HBDs. The dashed line shows the optimal cut-off value from the ROC curve. Two patients were assigned 
as HBDs, one of whom had a CTC count of 35. Most probably this is the result of a technical error in the enrichment of the CTCs or the 
gene profiling. Two HBDs had an epithelial score slightly above the cut-off value and were assigned as patients. D. The epithelial scores 
were calculated for the patients selected for the current study with FFPE primary tumors and liver metastases. Of the 36 patients, 23 had a 
score above the cut-off and were designated as having an “HBD”-unlike profile. These patients were included in the analyses to compare 
the gene expression profiles of the CTCs to the primary tumors and the liver metastases.
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Table 1: Clinicopathological characteristics of the 23 patients with “HBD-unlike” profiles.
N %*
Total 23 100%
Age at inclusion (mean ± sd) 68 ± 10
Sex (Male / female) 16 / 7 70% / 30%
Location primary tumor
  Right hemicolon 6 26%
  Left hemicolon / sigmoid 12 52%
  Rectum 5 22%
Staging
  T2 3 13%
  T3 16 70%
  T4 2 9%
  Unknown 2 9%
  N0 9 39%
  N1-2 11 49%
  Unknown 3 11%
Differentiation
  Well differentiated 1 4%
  Moderately differentiated 15 65%
  Poorly differentiated 1 4%
  Unknown 6 26%
Presentation with metastases
  Synchronous 12 52%
  Metachronous 11 48%
  Median interval (IQR ) 25 (17 – 39)
Liver metastases only 21 91%
Dukes classification at first diagnosis
  A 1 4%
  B 4 17%
  C 5 22%
  D 12 52%
  Unknown 1 4%
Prior chemotherapy
  Neoadjuvant 1 4%
  Adjuvant 3 11%
  Induction 7 30%
Primary tumor in situ at CTC draw 4 17%
Number of CTCs before liver surgery 
(median, IQR)
1 (0-3)
  ≥3 CTCs 6 26%
* Percentages do not always add up to 100% due to rounding
IQR = interquartile range; sd = standard deviation.
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Figure 3: Heatmaps showing the ranks per gene, per sample, per patient. Expression levels for individual genes have been 
ranked per sample over the 23 patients; undetectable expression levels have been given a rank number of 30. Red represents higher than 
median gene expression levels, white represents the median gene expression, and blue represents expression levels below the median or 
wholly undetectable.
Table 2: Correlation coefficients from Spearman correlation analyses comparing the ranked 25 gene profiles from 
the CTCs, the primary tumor, and the liver metastasis per patient
Patient Spearman r CTCs 
closest to
Clinical parameters
PT-
CTC
M-CTC PT-M CTC count PT in 
situ
Prior chemo Presentation 
with M
Number of M
1 0.08 0.08 0.55 Neither 0 N N Synchr 3
2 -0.18 0.12 -0.13 M 2 N Y Metachr 1
3 0.17 0.32 -0.21 M 0 N Y Synchr 1
4 -0.41 0.17 0.15 M 7 N Y Metachr 1
5 0.05 0.12 0.50 M 8 N Y Synchr 1
6 0.23 -0.45 0.01 PT 1 N N Synchr 1
7 0.33 0.43 -0.10 M 1 N N Metachr 1
8 0.24 0.37 0.42 M 0 Y N Synchr 2
9 0.20 0.21 -0.01 Both 0 N N Metachr 1
10 -0.11 0.28 0.26 M 0 Y N Synchr 1
11 0.13 0.42 0.43 M 0 Y N Synchr 2
12 0.13 0.03 0.54 PT 0 N Y Synchr 7
13 0.05 0.43 0.55 M 2 N Y Synchr 2
14 0.15 0.12 -0.38 Both 0 N Y Metachr 2
15 0.58 0.30 0.14 PT 8 N N Metachr 1
16 0.15 -0.09 0.77 PT 3 N N Metachr 1
17 0.25 0.31 0.59 Both 2 N N Synchr 2+
18 0.19 0.08 0.12 PT 0 Y Y Synchr 4+
(Continued )
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Several studies have compared the characteristics 
of CTCs to the primary tumors in different solid tumors, 
including mCRC. For example, mutations in the KRAS 
oncogene were found to be discordant between CTCs 
and primary tumors from mCRC patients in 6-55% of 
patients [27-31]. This discordance has been interpreted as 
tumor heterogeneity and a reflection of the characteristics 
of metastatic lesions instead of the primary tumor by the 
CTCs. However, solid proof that CTCs can indeed function 
as surrogates for metastatic tumor cells and thus prove to 
be a reliable alternative for tissue biopsies is lacking. Few 
studies have made direct comparisons between CTCs, the 
primary tumor, and distant metastatic tissue. In a study 
on metastatic breast cancer, the expression of the estrogen 
receptor was concordant between the CTCs and the 
primary tumor in 15 of the 22 (68%) patients and between 
Patient Spearman r CTCs 
closest to
Clinical parameters
PT-
CTC
M-CTC PT-M CTC count PT in 
situ
Prior chemo Presentation 
with M
Number of M
19 -0.14 0.13 0.16 M 1 Y N Synchr 1
20 -0.15 0.04 0.16 Neither 0 N N Metachr 1
21 0.33 0.44 0.58 M 3 N N Metachr 2
22 -0.02 0.35 0.16 M 6 N Y Metachr >10
23 0.06 0.56 -0.06 M 1 N Y Metachr 3
The cut-off value of r>0.1 was used to consider two profiles concordant. To assess whether a CTC profile was closer to 
the liver metastasis than to the primary tumor the difference between the correlation coefficients of the CTCs versus the 
primary tumor and the CTCs versus the liver metastasis had to be >0.1. The clinical parameters tested for the associations 
with the strength of correlation have been specified per patient. CTC= circulating tumor cells; M = metastasis; PT = primary 
tumor; Synchr = synchronous; Metachr = metachronous.
Table 3: Associations between clinical parameters and the strength of the correlation between two tumor samples 
(CTCs versus primary tumor, CTCs versus liver metastasis, or liver metastasis versus primary tumor)
N CTC-PT CTC-M M-PT
Mean r P Mean r P Mean r P
Mean all patients 23 0.10 0.21 0.23
Synchronically metastasized 11 0.11 0.90 0.18 0.50 0.33 0.12
Metachronically metastasized 12 0.09 0.24 0.12
Solitary metastasis 12 0.06 0.33 0.13 0.10 0.14 0.18
Multiple metastases 11 0.14 0.29 0.32
Mean primary tumor in situ 5 0.06 0.60 0.26 0.47 0.28 0.47
Mean primary tumor resected 18 0.11 0.19 0.21
Prior chemotherapy received 10 0.02 0.10 0.23 0.69 0.12 0.17
No chemotherapy received 13 0.16 0.19 0.30
Linear correlations
  Age 23 0.27 0.22 -0.02 0.94 -0.15 0.49
   Interval between surgery for 
PT and M*
12 0.16 0.61 0.24 0.45 -0.44 0.15
For the categorical variables, the reported r values are the mean correlation coefficients from the Spearman rank correlation 
of the 25 gene profiles. The P values are from independent samples t tests. For the continuous variables of age and interval 
between the two surgeries, the reported r and P-values are from linear correlations between the variables and correlation 
coefficients from the 25 gene profiles. CTC= circulating tumor cells; M = metastasis; PT = primary tumor.
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Table 4: List of the 34 genes that made up our “CTC-specific” gene panel that proved to be reliably measurable in 
CTCs in a background of leukocytes [8]
ID Gene Name Included in final 
panel?
CTC-PT CTC-M M-PT
Mean Δrank P Mean Δrank P Mean Δrank P
1 AGR2 Yes -2.39 0.43 -2.09 0.45 -0.30 0.90
2 AKR1C3 Yes -2.30 0.45 -3.39 0.29 1.09 0.73
3 CD44 No*
4 CDH1 Yes -10.52 0.02 -11.26 0.001 0.74 0.85
5 CDH17 Yes -8.17 0.03 -7.91 0.05 -0.26 0.89
6 CDH5 Yes 1.48 0.61 1.04 0.66 0.43 0.88
7 CDX1 Yes -11.09 0.001 -11.13 0.004 0.04 0.98
8 CEACAM5 Yes -11.09 0.002 -11.17 0.004 0.09 0.97
9 COL4A1 Yes -3.00 0.21 -3.04 0.32 0.04 0.98
10 CXCL1 Yes -4.43 0.12 0.00 1.00 -4.43 0.19
11 EGFR No*
12 FABP1 Yes -7.35 0.02 -7.35 0.02 0.00 1.00
13 FCGBP Yes -11.26 0.02 1.13 0.68 -12.39 0.004
14 GPX2 Yes -0.96 0.75 -1.78 0.48 0.83 0.76
15 HOXB9 No*
16 IGFBP3 Yes -11.09 0.003 -11.09 0.002 0.00 1.00
17 IGFBP4 Yes -7.61 0.02 -6.43 0.08 -1.17 0.73
18 IGFBP5 Yes -1.00 0.65 -1.00 0.63 0.00 1.00
19 KRT19 Yes -1.09 0.70 -1.09 0.65 0.00 1.00
20 KRT20 Yes -4.26 0.14 -3.61 0.23 -0.65 0.75
21 KRT8 No*
22 LAD1 Yes -2.48 0.38 -2.48 0.22 0.00 1.00
23 MACROD1 Yes -1.30 0.72 -2.35 0.45 1.04 0.72
24 MAPT Yes -14.48 0.001 -12.52 0.003 -1.96 0.52
25 NQO1 No*
26 PRSS8 Yes -1.52 0.54 -1.52 0.51 0.00 1.00
27 RARRES2 Yes -5.00 0.10 -5.00 0.11 0.00 1.00
28 REG1A No*
29 S100A16 No*
30 S100P Yes 1.17 0.68 3.65 0.17 -2.48 0.06
31 SATB2 No*
32 SLC6A8 No*
33 TRIM2 Yes -5.70 0.08 -5.70 0.06 0.00 1.00
34 TSPAN8 Yes -1.96 0.48 -1.30 0.57 -0.65 0.81
* Performed poorly on FFPE tissues in the multiplexed RT-qPCR (linear correlation, r<0.7 and P>0.05).
To allow for comparison between the FF CTC samples and the FFPE tumor samples, all Taqman assays were tested on matching FF and FFPE primary tumors 
from 15 patients. Only genes with correlating expression levels in the matching tissues (linear correlation r>0.7 and P<0.05) were included in the final gene panel. 
In total, 25 of the 34 genes were deemed reliably measurable in all samples and tissues and these genes were used to compare the characteristics of the CTCs to 
the corresponding FFPE primary tumor and liver metastasis. All individual gene expression levels were ranked over the 23 patients per sample and Δranks of one 
gene between two corresponding samples from a patient were calculated. The mean Δranks for the 25 genes across the 23 patients are shown in columns 4 (mean 
difference between the CTCs and the primary tumors), 6 (mean difference between the CTCs and the liver metastases), and 8 (mean difference between the primary 
tumors and the liver metastases). The mean Δranks were then tested by one-sample t tests with 1,000k bootstrapping against the 0 value; the resulting P values can be 
found in the columns 5, 7, and 9. Where there was no significant difference in the average expression of a gene between two samples, the mean Δrank would be close 
to and not statistically significantly different from 0. CTC= circulating tumor cells; M = metastasis; PT = primary tumor.
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the CTCs and the metastases in 10 of the 12 (83%) patients 
[32]. Notably, in the two patients where the metastasis was 
discordant from the primary tumor, the CTCs reflected the 
characteristics of the metastasis. In mCRC, the profiles 
from single CTCs – obtained with a micromanipulator 
after CellSearch-enrichment, followed by whole genome 
amplification, array comparative genomic hybridization 
and ultradeep sequencing – were compared to the primary 
tumors and distant metastatic sites of three patients [33]. 
In one patient, the copy number profile of a single CTC 
was 73% concordant with the liver metastasis, and 70% 
with the primary tumor. In the second patient, the CTCs 
were much closer to the primary tumor, while in the third 
patient all three profiles closely matched. These results 
seem comparable to the results from our study in that they 
support the hypothesis that CTCs are representative for 
metastatic tissue.
Still, our analyses should be considered exploratory 
since formal statistical analyses were restricted by the 
sample size and lack of preliminary data needed for upfront 
power calculations. Technical issues – mainly caused by 
the rarity of CTCs in the blood stream and the leukocyte 
contamination even after CellSearch enrichment – limited 
the number of genes that could be measured and compared. 
Nevertheless, we were able to build a CTC-specific gene 
panel through selection of mCRC-associated genes from 
literature and testing for absent or low-level expression 
in leukocytes. Tumor heterogeneity and sampling bias 
could also be an influence on the results. Only one liver 
metastasis was profiled per patient, even from patients in 
whom multiple metastases were present. The number of 
CTCs that were detected was low and, due to stochastic 
variations, only a subset of CTCs from the total circulating 
CTC pool may have been interrogated. Furthermore, 
the biological behaviors of tumor subclones may differ, 
whereby smaller, but more aggressive clones may shed 
more CTCs than an abundant, but more indolent clone, 
which might be overrepresented in a tissue biopsy. To 
address the aforementioned issues, future studies should 
incorporate more extensive sampling of tumor tissues and 
compare the profiles to single CTC profiles, preferably 
though an RNA sequencing approach to gain better insight 
into oncogenic and mutagenic genes and pathways.
In conclusion, CTCs from the majority of patients 
with mCRC reflected the characteristics of the liver 
metastasis, supporting the use of CTCs as a surrogate for 
metastatic biopsies. The CTCs, overall, resembled the 
molecular characteristics of the liver metastasis better 
than the primary tumor. Several CTC-specific changes 
occurred and seemed to primarily represent EMT-related 
downregulations of cell-adhesion and tumor suppressor 
genes, which could have a biological function for CTC 
survival and migration. Our results support the hypothesis 
that CTCs may become a valuable tool for precision 
medicine by functioning as a liquid biopsy and providing 
real-time information on tumor characteristics.
MATERIALS AND METHODS
Patients
Patients were retrospectively selected from a 
previously reported prospective clinical trial investigating 
the prognostic value of CTC enumeration for the one-
year recurrence rate in patients with mCRC undergoing 
a liver metastasectomy [10]. The selection of patients for 
the current study is shown in Figure 1. The Erasmus MC 
Review Board approved the study (METC 06-089). All 
patients provided written informed consent.
Sample collection and processing
Archived FFPE primary tumors and liver metastases 
were collected from pathology laboratories. The High-
Pure RNA Paraffin Kit (Roche Applied Science, Penzberg, 
Germany) was used according to the manufacturer’s 
instructions to isolate RNA from tumors with ≥30% tumor 
cells on HE staining. The details of blood sampling and 
processing for the CTC enumeration and characterization 
have been described before [10, 34]. In brief, two samples 
of 30 mL blood in CellSave (Janssen Diagnostics, Raritan, 
NJ) and EDTA tubes were taken just prior to liver surgery 
and processed <24 h using the CellSearch System. The 
higher volume of blood used to enumerate CTCs from 
when compared to the usual 7.5 mL was part of the design 
of the original study and has been described before [34]. 
After a modified Ficoll density-gradient separation, 
mononuclear cells were collected and processed by the 
CellSearch System using the Epithelial Cell Kit for the CTC 
enumeration and the Profile Kit for the CTC isolation (both 
kits Janssen Diagnostics, Raritan, NJ). The isolation of 
mRNA from CTC samples was performed using the AllPrep 
DNA/RNA Micro Kit (Qiagen, Venlo, The Netherlands).
The gene expression profiles from all the CTC 
samples from all patients included in the prospective trial 
were determined in our previous study [8]. A panel of 34 
CTC-specific genes was identified and proved to be reliably 
measurable in CTCs in the background of leukocytes. 
The genes had been selected based on literature for their 
association with mCRC development and progression. They 
were tested for absent or low-level expression in leukocytes, 
thereby rendering them measurable in the few CTCs present 
in the CellSearch-enriched samples. For the current study, 
we used the same panel of 34 genes for the selected primary 
tumor and liver metastasis tissues. The Taqman-based RT-
qPCR assays used on the CTC samples were tested for 
performance on FFPE tumor tissue by comparing a separate 
group of 15 patient-matched fresh-frozen (FF) and FFPE 
tumor tissues. Only assays with significantly correlating 
expression levels (linear correlation r>0.7, P<0.05) were 
included in the final gene panel, which resulted in 25 of 
the 34 genes suitable for use in the comparison of the CTC, 
primary tumor, and metastasis profiles (Table 4).
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Next, we selected patients with truly CTC-driven 
profiles from the total of 36 with available tissue profiles. 
Stochastic variations occurring in small numbers, such 
as CTC numbers from blood, limited the use of the CTC 
count to select patients with presumed circulating tumor 
content in the blood tube used for profiling. Instead, we 
constructed an epithelial score comprising the sum of 
the 34 epithelial genes’ measured expression levels in 
a CellSearch-enriched sample multiplied by the z-value 
from non-parametric comparisons of the median Cq values 
between the 23 patients with ≥3 CTCs and 30 HBDs from 
the previous study [8].
∑34 genes = −(−2.28 * AGR2 + 2.61 * AKR1C3 
− 3.56 * CD44 + 2.28 * CDH1 − 2.53 * CDH17 − 2.73 
* CDH5 − 2.68 * CDX1 − 1.95 * CEACAM5 − 2.38 * 
COL4A1 + 3.09 * CXCL1 − 1.64 * EGFR − 4.38 * FABP1 
+ 2.39 * FCGBP − 3.98 * GPX2 − 1.62 * HOXB9 + 2.5 
* IGFBP3 + 2.62 * IGFBP4 − 2.77 * IGFBP5 − 3.1 * 
KRT19 − 3.34 * KRT20 − 3.69 * KRT8 − 3.74 * LAD1 + 
1.08 * MACROD1 + 2.84 * MAPT + 2.51 * NQO1 − 3.25 
* PRSS8 − 1.89 * RARRES2 − 2.21 * REG1A − 3.94 * 
S100A16 + 1.94 * S100P − 2.7 * SATB2 + 2.32 * SLC6A8 
− 2.7 * TRIM2 − 3.27 * TSPAN8).
The epithelial score had a strong correlation with 
the CTC count from the parallel enumeration blood tube 
(Spearman r=0.76, P<0.001, Figure 2A), indicating that 
the score did indeed reflect the epithelial input into the 
PCR. A cut-off score to identify patients with CTC-driven 
gene expression profiles was then determined from the 
Receiver Operating Characteristics (ROC) curve of the 
23 patients with ≥3 CTCs versus 30 HBDs (Figure 2B). 
The optimal cut-off yielded a sensitivity of 91% and a 
specificity of 93% to discriminate patients from HBDs and 
was used to select patients with an “HBD-unlike” profile 
for the current study (Figure 2C and 2D).
Normalization and statistical analysis
Three reference genes (GUSB, HMBS, HPRT1) 
were used as controls for sufficient overall mRNA quality 
(average reference gene Cq<26 in 92% of the samples in 
total). Following the ΔCq method, expression levels were 
normalized relative to the average Cq of the reference 
genes [35]. The median ΔCq of each gene transcript from 
the 30 HBDs was used as the cut-off to correct for the 
leukocyte background in the CTC samples, as previously 
described [7, 8]. Different normalization approaches 
were tested in the first attempt to directly compare the 
gene expression levels of the CTC and FFPE samples. 
However, non-measurable levels in the CTC samples 
distorted these normalization procedures, forcing us 
to continue non-parametrically by separately ranking 
the Cq values of individual genes across the patients for 
the CTC, primary tumor, and liver metastasis samples 
separately. The three resulting ranks per gene per patient 
were visualized in heatmaps (Figure 3). Spearman 
correlation coefficients were calculated between the 25 
gene profiles and considered as continuous variables 
with r=1 representing absolute concordance and r=-1 
representing absolute discordance. A cut-off value to 
cite two profiles as concordant was chosen based on the 
mean of all correlation coefficients; the mean r was 0.1 
and, consequently, all profiles with r>0.1 were considered 
concordant. Differences between categorical variables 
were tested by χ2 or Fisher exact tests. The differences 
in gene expression between two samples were tested by 
one-sample t tests. All statistical tests were two-sided 
and performed with 1,000k bootstrapping to correct for 
multiple testing; P<0.05 was considered statistically 
significant. The Datan Framework GenEx Pro package 
version 5.4.1 software (MultiD Analyses AB, Göteborg, 
Sweden) and SPSS 21.0 (IBM Corporation, Armonk, NY) 
were used for the analyses. The manuscript was written to 
conform with the reporting recommendations for tumor 
marker prognostic studies (REMARK; [36]).
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